NOTE: An asterisk denotes an author who was a student, post-doctoral fellow, other trainee or research/clinical staff on Prof. Shaya’s team at the time of publication.
Greenberg Dotan S; Reuveni N; Tal A; Oksenberg A; Cohen A; Shaya FT; Tarasiuk A; Scharf SM. Increased Prevalence of Obstructive Lung Disease in Patients With Obstructive Sleep Apnea. Sleep and Breathing 2013.
Breunig IM*, Shaya FT, Hanna N, Seal B, Chirikov VV*, Mullins CD. Transarterial Chemoembolization Treatment: Association between Multiple Treatments, Cumulative Expenditures, and Survival. Value in Health, May 2013; 16 (3)3: A1-A2.
Shaya FT; Chirikov VV; Bron M; Howard D; Foster C; Yan X; Khanna N; Warrington VO. Comparison of Physician Practice Patterns for Older Adults Compared to NHANES Diabetes Cohort on Oral/other Therapy. Expert Review of Pharmacoeconomics & Outcomes Research 2013;13(1):153-60.
Shaya, FT; Chirikov, VV*; Mullins, CD; Shematek, J., Howard D*; Foster C*; Saunders, E. Social Networks Help Control Hypertension. The Journal of Clinical Hypertension 2013; 15:34–40.
Breunig IM*, Shaya FT, Scharf SM. “Delivering Cost-Effective Care for COPD in the United States: Recent Progress and Current Challenges.” Expert Review of Pharmacoeconomics & Outcomes Research 2012; 12(6): 725-735.
Shaya FT, Breunig IM*, Scharf SM. The Use of Age-Period-Cohort Analysis to Determine the Impact of Economic Development on COPD Mortality in Hong Kong. Expert Review of Pharmacoeconomics & Outcomes Research, 2012; 12(1): 19-21.
Mullins CD; Shaya FT; Blatt L; Saunders E. A Qualitative Evaluation of a Citywide Community Health Partnership Program. Journal of the National Medical Association 2012; 104(1-2):53-60.
Shaya FT; Chirikov VV*. Decision support tools to optimize economic outcomes for type 2 diabetes. Am J Manag Care, 2011. 17 Suppl 14: p. S377-83.
Johnson, W., Shaya, F. T., Khanna, N., Warrington, V. O., Rose, V. A., Yan, X., Bailey-Weaver, B., Mullins, C. D. and Saunders, E. The Baltimore Partnership to Educate and Achieve Control of Hypertension (The BPTEACH Trial): A Randomized Trial of the Effect of Education on Improving Blood Pressure Control in a Largely African American Population. The Journal of Clinical Hypertension, 13: 563–570. 2011
Shaya FT, Gbarayor CM*, Laird A, Winston RA, Saunders E. Diabetes Knowledge in a High Risk Urban Population. Ethnicity & Disease, 2011; 21(4):485-489.
Onwudiwe NC*, Mullins CD, Winston RA, Shaya FT, Pradel FP, Laird A, Saunders E. Barriers to Self-management of Diabetes: A Qualitative Study among Low-income Minority Diabetics. Ethnicity & Disease; 21(1-2), 2011.
Onukwugha EO, Mullins CD, Weir MR, Loh E*, Shaya FT, Saunders E. Readmissions after Unauthorized Discharges in the Cardiovascular Setting. Medical Care; 49(2):215-224, February 2011.
Gbarayor CM*, Winston RA, Laird A, Shaya FT, Mullins CD, Saunders E. Empowering Cultural Competence in a Community-based Participatory Research Model: A Strategy to Enhance the Physician-Patient Relationship. The Journal of Participatory Medicine, September 2010.
Shaya FT, Yan X*, Farshid M*, Barakat S*, Jung M*, Low S*, Fedder D. Social Networks in Cardiovascular Disease Management. Expert Review of Pharmacoeconomics and Outcomes Research; 10(6):701-705, 2010 December.
Brandes DW, Shaya FT, Pill MW. Quantifying the Role of Natalizumab in Health and Economic Outcomes in Multiple Sclerosis. American Journal of Managed Care; 16 (16): S171-S177, 2010 June.
Bivins A*; Hou K*; Ayesu N*; Ellsworth B*; Montenegro S*; Tu X*; Boyle C; Dowling T; Shaya FT. Clinical Evaluation of Natalizumab for Formulary Consideration. Expert Opinion on Biological Therapy; 10(8):1279-87, 2010 August. PMID: 20626228
Shaya FT, Yan X*, Lin P*, Simoni-Wastila L, Bron M, Baran R, Donner T. U.S. Trends in Glycemic Control, Treatment and Comorbidity Burden in Patients with Diabetes. Journal of Clinical Hypertension; 12(10):826-832, 2010 October. DOI: 10.1111/j.1751-7176.2010.00365.x
Bakhshai J*, Bleu-Lainé R*, Jung M*, Lim J*, Reyes C*, Sun L*, Rochester C, Shaya FT. The Cost Effectiveness and Budget Impact of Natalizumab for Formulary Inclusion. Journal of Medical Economics; 13(1):63–69, 2010 March.
Lin P*, Shaya FT, Scharf SM. Economic Implications of Comorbid Conditions among Medicaid Beneficiaries with COPD. Respiratory Medicine; 104(5):697-704, 2010 May. DOI:10.1016/j.rmed.2009.11.009
Onukwugha E; Shaya FT; Saunders E; Weir MR. Ethnic Disparities, Hospital Quality, and Discharges against Medical Advice among Patients with Cardiovascular Disease. Ethnicity & Disease;19(2):172-178, 2009.
Shaya FT, Du D*, Gbarayor CM, Frech-Tamas F, Lau H, Weir M. Predictors of Compliance with Antihypertensive Therapy in a High Risk Medicaid Population. Journal of the National Medical Association (JNMA); 101(1):34-39, 2009 January.
Shaya FT; Lin P*; Aljawadi M*; Scharf SM. Elevated Economic Burden in Obstructive Lung Disease Patients with Concomitant Sleep Apnea Syndrome. Sleep & breathing = Schlaf & Atmung;13(4):317-323, 2009 November. DOI: 10.1007/s11325-009-0266-2
Shaya FT, Maneval MS*, Gbarayor CM*, Sohn K*, Dalal A, Du D*, Scharf SM. Burden of COPD, Asthma, and Concomitant COPD and Asthma among Adults Racial Disparities in a Medicaid Population. CHEST; 136(2):405-411, 2009 August. DOI: 10.1378/chest.08-2304
Shaya FT; Low S*; Barakat S*; Farshid M*; Jung M*; Norman N*; Fedder DO. Case for a Pharmacy-Centered Medical Home. Expert Review of Pharmacoeconomics & Outcomes Research; 9(5):397-399, 2009 October.
Shaya FT, Lv Z*, Sohn K*, Weir MR. Thiazolidinediones and Cardiovascular Events in High-Risk Patients with Type-2 Diabetes Mellitus: A Comparison with Other Oral Antidiabetic Agents. P&T; 34(9): 490-494, 499-501, 2009 September. PMCID: PMC2799132
Blanchette CM*, Simoni-Wastila L, Shaya FT, Orwig D, Noel J, Stuart B. Health Care Use in Depressed, Elderly, Cardiac Patients and the Effect of Antidepressant Use. American Journal of Health-System Pharmacy (AJHP); 66(4):366-372, 2009.
Blanchette CM*, Simoni-Wastila L, Shaya FT, Orwig D, Noel J, Stuart B. Depression Following Thrombotic Cardiovascular Events in Elderly Medicare Beneficiaries: Risk of Morbidity and Mortality. Cardiology Research and Practice;194528, 2009.
Robertson T*, Cook C, Shaya FT, Lee H, Wang J*. Impact of Medication Burden on Persistence of Lipid Lowering Drugs. American Journal of Managed Care; 14(11):31-41, 2008 November.
Shaya FT, Du D*, Frech-Tamas F, Lau H, Fatodu H, Garber H. Predictors of Fixed-Dose Combination Antihypertensive Drug Therapy in a Medicaid Population. Journal of the American Society of Hypertension (JASH); 2(6):469-475, 2008 November. DOI: 10.1016/j.jash.2008.04.011
Shaya FT, Du D*, Akazawa M, Blanchette C, Wang J*, Mapel D, Dalal A, Scharf S. Burden of Concomitant Asthma and COPD in a Medicaid Population. CHEST; 134(1):14-19, 2008 July. DOI: 10.1378/chest.07-2317
Shaya FT, Gbarayor CM*, Flores D*, Wang J*, Norman N*.School-based Obesity Interventions: A Literature Review. Journal of School Health; 78 (4):189-196, 2008 April. DOI: 10.1111/j.1746-1561.2008.00285.x
Kane S, Shaya FT. Medication Non-adherence is associated with Increased Medical Health Care Costs.
Digestive Diseases and Sciences; 53(4):1020-1024, 2008 April. DOI: 10.1007/s10620-007-9968-0
Shaya FT, Aljawadi M*. Diabetic Retinopathy. Clinical Ophthalmology; 1(3):259 – 265, 2007 December. DOI 10.2147/OPTH.S
Shaya FT, Onwudiwe N*, Samant N*, Winston R, Johnson W, Laird A, Larkins F, Shaya GE. Foot Self-Check and Diabetes Awareness. P&T; 32(11):614-615, 620, 2007 November.
Shaya FT, Sohn K*, Bleu-Laine R*, Casciano M*, Lee S*, Lim J*. Clinical and Economic Evaluation of Exanatide Injection for the Treatment of Type Two Diabetes. Journal of Medical Economics; 10(4):529-537, 2007.
Shaya FT, Gu A*, Saunders E. Metabolic Syndrome Prevalence in an Urban African America Population. Diabetes and Metabolic Disorders: Clinical Research and Reviews; 1(3):151-157, 2007 September.
Shaya FT, Gu A*. Critical Assessment of Intent-to-Treat Analyses. Journal of Medical Economics; 10(2): 171-177, 2007 July.
Wang J*, Mullins CD, Mamdani M, Rublee D, Shaya FT. New Diagnosis of Hypertension among Celecoxib and Non-Selective NSAID Users: a Population-Based Cohort Study. Annals of Pharmacotherapy; 41(6): 937-943, 2007 June. DOI 10.1345/aph.1H659
Shaya FT, Samant N*, Pradel F, Mullins CD, Scharf S, Britt E. Health-Related Quality of Life as a Potential Predictor in Chronic Obstructive Lung Disease Patients. Expert Review of Pharmacoeconomics and Outcomes Research; 7(2):129-135, 2007 April. PMID: 20528439
Shaya FT, Ohsfeldt R. Bridging the Gap between Pharmacoeconomics and the Real World Practice of Managed Care Pharmacy (Editorial). Journal of Managed Care Pharmacy; 13(1):37-43, 2007 January/February. PMID: 17269839
Shaya FT, Wang J*, Casciano M*, Lee S*, Levine A*, Varghese R*. Clinical and Economic Evaluation of Olanzapine-Fluoxetine HCl Combination in the Treatment of Bipolar Depression: A Managed Care Approach. Journal of Medical Economics; 10(1):67-77, 2007 April.
Shaya FT, Gbarayor C*, Yang HK, Agyeman-Duah M*, Saunders E. A Perspective on African American Participation in Clinical Trials. Contemporary Clinical Trials; 28(2):213-217, 2007 February. DOI:10.1016/j.cct.2006.10.001
Mullins CD, Kuznik A*, Shaya FT, Obeidat NA*, Levine AR*, Liu LZ, Wong W. Cost-Effectiveness Analysis of Linezolid Compared with Vancomycin for the Treatment of Nosocomial Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus. Clinical Therapeutics; 28(8):1184-98, 2006 August. DOI:10.1016/j.clinthera.2006.08.016.
Wang J*, Noel JM, Zuckerman IH, Miller NA, Shaya FT, Mullins CD. Disparities in Access to Essential New Prescription Drugs between Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanic Whites. Medical Care Research and Review; 63(6):742-763, 2006 December. DOI: 10.1177/1077558706293638
Wang J, Zuckerman IH, Miller NA, Shaya FT, Noel JM, Mullins CD. Utilizing New Prescription Drugs: Disparities among non-Hispanic Whites, non-Hispanic Blacks, and Hispanic Whites. Health Services Research; 42 (4): 1499-1519. 2006 August 7. DOI: 10.1111/j.1475-6773.2006.00682.x
Shaya FT, Shaya KE. Access to Medications in the Middle East. The Lancet; 367(9525), 2006 June.
Shaya FT, El Khoury AC*, Mullins CD, Du D*, Skolasky R, Fatodu H, Garber H, Weir M. Drug Therapy Persistence and Stroke Recurrence. American Journal of Managed Care; 12(6):313-319, 2006 June. PMID: 16756450
Shaya FT, Gbarayor CM*. The Case for Cultural Competence in Health Professions Education. American Journal of Pharmaceutical Education; 70(6): article 124, 2006 December 15. PMCID: PMC1803701
Shaya FT, Deshpande G*. New Treatment Approaches to Diabetes. Managed Care; 15(5):38,40-41, 2006 May. PMID: 16749518
Shaya FT, El Khoury AC*, Wong W, Whitelaw N, Whitelaw G, Joseph R, Cohen E.Persistence with Pharmacotherapy for Gastrointestinal Disease: Associated Costs of Health Care. P&T; 31(11):657-665, 2006 November. ISSN 1052-1372
Shaya FT, Gbarayor CM*. Adjusting for Risk and Confounding in Outcomes and Effectiveness Studies. Expert Review of Pharmacoeconomics & Outcomes Research; 6(2):109-110, 2006 April. ISSN 1473-7167
Shaya FT, El Khoury AC*, Samant N*, Scharf S. Utilization of Healthcare Resources in a High-Risk Population with Chronic Obstructive Pulmonary Disorder. P&T; 31(5):261-268, 2006 May.
Shaya FT, Yi G*, El-Khoury AC*, Lee S*, Callaway S*, Levine A*. Clinical and Economic Considerations for Teriparatide: a Managed Care Approach. Journal of Drug Assessment; 9(1):3-13, 2006 March.
Mullins CD, Shaya FT, Meng F, Wang J, Bron MS. Comparison of First Refill Rates among Users of Sertraline, Paroxetine, and Citalopram. Clinical Therapeutics; 28(2): 297-305, 2006 February. DOI:10.1016/j.clinthera.2006.02.006
Shaya FT, Gu A*. Deriving Effectiveness Information for Decision Making. Expert Review of Pharmacoeconomics & Outcomes Research; 6(1):5-7, 2006 February. Invited, non peer-reviewed, editorial DOI:10.1586/14737184.108.40.206
Mullins CD, Shaya FT, Zito JM, Obeidat N, Naradzay J, Harrison DJ. Effect of Initial Ziprasidone Dose on Treatment Persistence in Schizophrenia. Schizophrenia Research; 83(2-3):277-284, 2006 April.
Shaya FT, Gu A*, Saunders E. Addressing Cardiovascular Disparities through Community Interventions. Ethnicity and Disease; 16(1):138-144, 2006 January. ISSN 1049-510X
Finkelstein J, Shaya FT, Arora M, Joshi A, Samant N*, Scharf S. Automated Survey Collector (ASC): A Universal Platform for Interactive Collection of Clinical Data. Journal of Systemics, Cybernetics and Informatics; 39(1):101-104, 2005.
Shaya FT. Compliance with Medicine. Ophthalmology Clinics of North America; 18(4):611-617, 2005 December.
Shaya FT, Samant N*, Skolasky R, Saunders E. Modeling Risk of Gastrointestinal Events Among Medicaid NSAID Users, Using Propensity Scores. Expert Review of Pharmacoeconomics & Outcomes Research; 5(5):625-632, 2005 October.
Shaya FT, Jones-Calloway S*, El Khoury AC*, Tomety J*. Clinical and Economic Evaluation of Two Thiazolidinediones in the Management of Diabetes. P&T; 30(8):456-460, 2005 August.
Shaya FT. The Burden of Obstructive Lung Disease in Medicaid and Managed Care Populations. Managed Care; 14(7 Suppl Obstructive Lung):20-23, 2005 July. PMID: 18564561
El Khoury AC*, Shaya FT. Medicaid HMOs and Diabetes Care Outcomes. Drug Benefit Trends; 17(7):298-305, 2005 July.
Shaya FT, Blume S, Gu S*, Jumadilova Z, Zyczynski T. Persistence and Switch Patterns of Overactive Treatment Patterns in a Medicaid Managed Care Population. American Journal of Managed Care; 11(4 Suppl.):S121-S129, 2005 July.
Shaya FT, Klaskala W, Mullins CD. Review of Cost-Effectiveness Studies of Pegylated Therapies for Hepatitis C. Expert Review of Pharmacoeconomics & Outcomes Research; 5(3):339-351, 2005 June.
Shaya FT, Gu A*. Assessing Potential Risks and Valuing Expected Benefit. Managed Care Interface; 18(5):27-30, 2005 June. PMID: 15941187
Shaya FT, El Khoury AC*. Developing Benchmarks for Adherence Studies. Expert Review of Pharmacoeconomics & Outcomes Research; 5(3):229-232(4), 2005 June. Invited, non peer-reviewed, review work DOI 10.1586/14737220.127.116.11
Shaya FT, Shin J*, Mullins CD, El Khoury AC*, Garber H. Risk of Heart Failure with the Use of Thiazolidinediones within a Medicaid Population. Pharmacy and Therapeutics; 30(5):273-281, 2005 May.
Mullins CD, Shaya FT, Meng F, Wang J, Harrison D. Switching and Discontinuation of Sertraline, Paroxetine and Citalopram Therapy. Pharmacotherapy; 25(5):660-667, 2005 May.
Shaya FT, Shin J*, Mullins CD, Fatodu H, Gu A*, Saunders E. Disparities in the Use of Thiazolidinediones compared with Metformin. Journal of the National Medical Association; 97(4):493-7, 2005 April. PMCID: PMC2568710
Shaya FT, Samant N*, Kim J*. Non-Selective Cyclooxygenase Inhibition and Gastrointestinal Effects: a Review of Recent Clinical Observations. Medical Hypotheses and Research; 2(2):401-411, 2005 April.
Shaya FT, Blume SW, Blanchette CM*, Weir MR, Mullins CD. Selective Cyclooxygenase-2 Inhibition and Cardiovascular Effects: an Observational Study of a Medicaid Population. Archives of Internal Medicine; 165(2):181-186, 2005 January 24. PMID: 15668364
Shaya FT, Blume S*. Prescription for Cyclooxygenase-2 Inhibitor and Other Non-Steroidal Anti-inflammatory Agents in a Medicaid Managed Population: African Americans versus Caucasians. Pain Medicine; 6(1):11-17, 2005 January. DOI: 10.1111/j.1526-4637.2005.05011.x
Shaya FT, Kim J*. Off-Label Use is a Common though Underexamined Practice (Editorial). Drug Benefit Trends; 17(1):29-30, 2005 Jan.
Shaya FT, Grimes M*, Dhir S*, Levine A*, Yi G*. Economic Impact of Formulary Decisions: Case Study of Risedronate. Journal of Drug Assessment; 7(3):121-132, 2004 December.
Shaya FT, Samant N*. Cost Studies in Clinical Trials (Editorial). Expert Review of Pharmacoeconomics & Outcomes Research; 4(6):591-594, 2004 December. DOI 10.1586/1473718.104.22.1681
Shaya FT, Samant N*. Formulary Decision Methodology in the Context of Health System Costs and Insurance Trends (Editorial). Expert Review of Pharmacoeconomics & Outcomes Research;4(6):595-59, 2004 December. DOI:10.1586/1473722.214.171.1245
Shaya FT, Wong W, Shin JY*, Martin L, Samant N*. Formulary Decision-Making Considerations: COX-2 Inhibitors. Managed Care Interface; 17(11):29-36, 41, 2004 November. PMID: 15573802
Shaya FT, Blume S*, Mullins CD. Prescription Drug Spending Trends for the Privately Insured in Maryland, 2000-2001: Increases in Marylanders’ Out-of-Pocket Drug Spending Outpaced Overall Drug Spending in 2001 by Fifteen Percentage Points. Health Affairs; 23(5):226-232, 2004 September-October. DOI:10.1377/hlthaff.23.5.226
Shaya FT, Shin JY*, Wong W, Proveaux W.Clinical and Economic Evaluation of Gatifloxacin and Levofloxacin. Expert Review of Pharmacoeconomics & Outcomes Research; 4(4):469-477, 2004 August.
Shaya FT, Blume SW*, Blanchette CM*, Mullins CD, Foster S. Propensity to Prescribe COX-2 Inhibitors vs. other NSAIDS in a Medicaid MCO. Formulary; 39(6):320-321, 2004 June.
Mullins CD, Cooke JL Jr*., Wang J*, Shaya FT, Hsu DV, Brooks S. Disparities in Prevalence Rates for Lung, Colorectal, Breast, and Prostate Cancers in Medicaid. Journal of the National Medical Association; 96(6):809-16, 2004 June. PMCID: PMC2568358
Mullins CD, Shaya FT, Flowers LR, Saunders E, Johnson W, Wong W. Health Care Cost of Analgesic Use in Hypertensive Patients. Clinical Therapeutics; 26(2):285-93, 2004 February. DOI:10.1016/S0149-2918(04)90027-6
Mullins CD, Ndiritu E, Yoder D, Shaya FT, Taylor T. Impact of the Fourth Hurdle on the International Pharmaceutical Industry. Expert Review of Pharmacoeconomics and Outcomes Research; 3(2):169-177, 2003 August.
Shaya FT, Mullins CD, Wong W. Summary Quality Scores for Pharmacoeconomic Studies: Balancing Validity with Need (Editorial). Journal of Managed Care Pharmacy; 9(1):87-8, 2003 January February.
Shaya FT, Mullins CD, Wong W. Incidence versus Prevalence Modeling in Pharmacoeconomics.
Expert Review of Pharmacoeconomics & Outcomes Research; 2(5):435-42, 2002 October. DOI: 10.1586/14737126.96.36.1995
Shaya FT, Mullins CD, Wong W, Cho J. Discontinuation Rates of Topical Glaucoma Medications in a Managed Care Population. American Journal of Managed Care; 8(10 Suppl.):S271-277, 2002 August.